Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Ina, Haendle"'
Autor:
Alexander Steinkasserer, Luca Beltrame, Gabi Theiner, Diana Dudziak, Gerold Schuler, Christian Ostalecki, Manuel Wiesinger, Stefanie Gross, Duccio Cavalieri, Stephan Schierer, Andreas Baur, Ina Haendle, Elisabeth Zinser, Gordon F. Heidkamp, Manfred B. Lutz, Beatrice Schuler-Thurner, Waltraud Leisgang, Eckhart Kämpgen, Michael Erdmann, Ansgar J. Pommer
Publikováno v:
Blood. 122:2185-2194
Denileukin diftitox (DD), a diphtheria toxin fragment IL-2 fusion protein, is thought to target and kill CD25(+) cells. It is approved for the treatment of cutaneous T-cell lymphoma and is used experimentally for the depletion of regulatory T cells (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5544b3a3b474656058fa8b2fc9a1958c
https://doi.org/10.1182/blood-2012-09-456988
https://doi.org/10.1182/blood-2012-09-456988
Autor:
Erwin Strasser, Stefanie Gross, Karl Sotlar, Lucie Heinzerling, Stefan Schliep, Ina Haendle, Pierre Coulie, Erwin S. Schultz, Steve Voland, Gerold Schuler, Peter Dankerl, Rolf Janka, Beatrice Schuler-Thurner, Thomas G. Berger, Michael Erdmann
Publikováno v:
JCI insight. 2(8)
Background Reports on long-term (≥10 years) effects of cancer vaccines are missing. Therefore, in 2002, we initiated a phase I/II trial in cutaneous melanoma patients to further explore the immunogenicity of our DC vaccine and to establish its long
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9d8581eb55824bddc0bc399d597e41e
https://pubmed.ncbi.nlm.nih.gov/28422751
https://pubmed.ncbi.nlm.nih.gov/28422751
Autor:
Rod Dunbar, Beatrice Schuler-Thurner, Jürgen Knop, Ina Haendle, Claudia Röder, Eckhart Kämpgen, Armin Bender, Helmut Jonuleit, Gerhard Schuler, Christian Maczek, Vincenzo Cerundolo, Eva-B. Bröcker, P. von den Driesch, Petra Keikavoussi, Waltraud Leisgang, Alexander Enk, Detlef Dieckmann
Publikováno v:
Scopus-Elsevier
Dendritic cell (DC) vaccination, albeit still in an early stage, is a promising strategy to induce immunity to cancer. We explored whether DC can expand Ag-specific CD8+ T cells even in far-advanced stage IV melanoma patients. We found that three to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74c6e2745b2bce21477b52d911544384
https://ora.ox.ac.uk/objects/uuid:b3385d39-f639-4e34-b662-f2c05b5b9375
https://ora.ox.ac.uk/objects/uuid:b3385d39-f639-4e34-b662-f2c05b5b9375
Autor:
Beatrice Schuler-Thurner, Kris Thielemans, Gerold Schuler, Erwin S. Schultz, C. Erfurt, Ina Haendle, Carlo Heirman, Zhaojun Sun, Pierre van der Bruggen
Publikováno v:
The Journal of Immunology. 178:7703-7709
To avoid immune escape by down-regulation or loss of Ag by the tumor cells, target Ags are needed, which are important for the malignant phenotype and survival of the tumor. We could identify a CD4+ T cell epitope derived from the human melanoma-asso
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c937a14a089691007debc22d8cc234d
https://doi.org/10.4049/jimmunol.178.12.7703
https://doi.org/10.4049/jimmunol.178.12.7703
Autor:
Werner Hohenberger, Gerold Schuler, Beatrice Schuler-Thurner, Per thor Straten, Thomas G. Berger, Jürgen C. Becker, Nicolas Bauer, Ina Haendle, Matthias Lüftl, Lars Østergaard Pedersen, David Schrama
Publikováno v:
International Journal of Cancer. 111:229-237
Anticancer immune therapies aim at the induction of tumor-specific T cells, which ultimately should kill tumor cells. The effector cells should, therefore, not only exert cytotoxic activity but also home to and infiltrate the tumor site. Hence, monit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8e56a72d2ff9741f35ca44dac0930492
https://doi.org/10.1002/ijc.20238
https://doi.org/10.1002/ijc.20238
Autor:
Beatrice Schuler-Thurner, Thomas G. Berger, Anke Glaser, Thomas L. Diepgen, Oliver Kuss, Ute Hirsch, Ina Haendle, Doris Schreiner, Gerold Schuler, Christian Maczek, Bernadette Feuerstein, Waltraud Leisgang, Claudia Röder
Publikováno v:
Journal of Immunological Methods. 245:15-29
Dendritic cells (DC) are increasingly used as a vaccine. Unfortunately, a satisfactory cryopreservation of DC in the absence of FCS is not yet available, so that laborious repeated generation of DC from fresh blood or frozen peripheral blood mononucl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3afa63a59ef10b92e798e328f131710
https://doi.org/10.1016/s0022-1759(00)00269-6
https://doi.org/10.1016/s0022-1759(00)00269-6
Autor:
Christian Maczek, Beatrice Thurner, Doris Schreiner, Eckhart Kämpgen, Peter von den Driesch, Detlef Dieckmann, Alexander Enk, Eva B. Bröcker, Helmut Jonuleit, Ralph M. Steinman, Gerold Schuler, Petra Keikavoussi, Ina Haendle, Armin Bender, Claudia Röder
Publikováno v:
The Journal of Experimental Medicine
Dendritic cells (DCs) are considered to be promising adjuvants for inducing immunity to cancer. We used mature, monocyte-derived DCs to elicit resistance to malignant melanoma. The DCs were pulsed with Mage-3A1 tumor peptide and a recall antigen, tet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3e4a520739d125e4644454f9ecf186e
https://doi.org/10.1084/jem.190.11.1669
https://doi.org/10.1084/jem.190.11.1669
Autor:
Thomas G, Berger, Ina, Haendle, David, Schrama, Matthias, Lüftl, Nicolas, Bauer, Lars Østergaard, Pedersen, Beatrice, Schuler-Thurner, Werner, Hohenberger, Per thor, Straten Pt, Gerold, Schuler, Jürgen C, Becker
Publikováno v:
International journal of cancer. 111(2)
Anticancer immune therapies aim at the induction of tumor-specific T cells, which ultimately should kill tumor cells. The effector cells should, therefore, not only exert cytotoxic activity but also home to and infiltrate the tumor site. Hence, monit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::32ae82c99531fef3b2cf72914a684e3e
https://pubmed.ncbi.nlm.nih.gov/15197776
https://pubmed.ncbi.nlm.nih.gov/15197776